[Treatment of Parkinson's disease with L-dopa].
D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001479:Basal Ganglia / Q000378:metabolism; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004402:Dysautonomia, Familial / Q000139:chemically induced; D006801:Humans; D009132:Muscles / Q000187:drug effects; D010276:Parasympatholytics / Q000008:administration & dosage; D010300:Parkinson Disease / Q000188:drug therapy*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013237:Stereoisomerism
D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D004298:Dopamine
Il trattamento del morbo di Parkinson con L-dopa.